Your browser doesn't support javascript.
loading
Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells.
Kelkar, Anita A; Butler, Javed; Schelbert, Erik B; Greene, Stephen J; Quyyumi, Arshed A; Bonow, Robert O; Cohen, Ira; Gheorghiade, Mihai; Lipinski, Michael J; Sun, Wei; Luger, Dror; Epstein, Stephen E.
Afiliación
  • Kelkar AA; Cardiology Division, Emory University, Atlanta, Georgia.
  • Butler J; Stony Brook University, Stony Brook, New York. Electronic address: javed.butler@stonybrookmedicine.edu.
  • Schelbert EB; Cardiology Division, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Greene SJ; Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Quyyumi AA; Cardiology Division, Emory University, Atlanta, Georgia.
  • Bonow RO; Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Cohen I; Stony Brook University, Stony Brook, New York.
  • Gheorghiade M; Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Lipinski MJ; MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC.
  • Sun W; MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC.
  • Luger D; MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC.
  • Epstein SE; MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC.
J Am Coll Cardiol ; 66(18): 2038-2047, 2015 Nov 03.
Article en En | MEDLINE | ID: mdl-26516007
Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease. Although encouraging outcome signals have been reported, these have been small, leading to uncertainty as to whether they will translate into significantly improved outcomes. A reassessment of the rationale for the use of stem cells in cardiovascular disease is therefore timely. Such a rationale should include analyses of why previous trials have not produced significant benefit and address whether mechanisms contributing to disease progression might benefit from known activities of stem cells. The present paper provides such a reassessment, focusing on patients with left ventricular systolic dysfunction, either nonischemic or ischemic. We conclude that many mechanisms contributing to progressive left ventricular dysfunction are matched by stem cell activities that could attenuate the myocardial effect of such mechanisms. This suggests that stem cell strategies may improve patient outcomes and justifies further testing.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiomiopatía Dilatada / Trasplante de Células Madre Tipo de estudio: Etiology_studies Límite: Humans Idioma: En Revista: J Am Coll Cardiol Año: 2015 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiomiopatía Dilatada / Trasplante de Células Madre Tipo de estudio: Etiology_studies Límite: Humans Idioma: En Revista: J Am Coll Cardiol Año: 2015 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos